Transcatheter pulmonary valve replacement offers a promising, less invasive option for patients with pulmonary valve dysfunction, with freedom from reintervention over 90% at 1 year.
Transcatheter pulmonary valve replacement is a less invasive option with promising short- and long-term outcomes for patients with dysfunctional pulmonary conduits or bioprostheses.
Transcatheter pulmonary valve replacement has changed the way we approach congenital and structural heart disease. In patients with a conduit between the right ventricle and pulmonary artery or a bioprosthetic pulmonary valve, there will eventually be pulmonary valve dysfunction. This leads to right ventricular failure and possibly arrhythmias. Due to prior operations and the comorbid conditions that these patients have, reoperation to replace the pulmonary valve is complicated and associated with greater morbidity and mortality than the initial operation. The percutaneous insertion of a stented bioprosthetic valve offers a less invasive option. The valve is inserted into the dysfunctional conduit/bioprosthetic valve via the femoral vein or internal jugular vein. Most patients are able to return home the following day without the prolonged recovery period that follows conventional open heart surgery. Both short- and long-term outcomes appear to be promising with freedom from reintervention over 90% at 1 y...
Holoshitz et al. (Thu,) conducted a review in Congenital and structural heart disease with pulmonary valve dysfunction. Transcatheter pulmonary valve replacement was evaluated on Freedom from reintervention. Transcatheter pulmonary valve replacement offers a promising, less invasive option for patients with pulmonary valve dysfunction, with freedom from reintervention over 90% at 1 year.